Category: 3. Business

Prince Group/Getty images

A startling rise

Getty Images

AFP via Getty Images

‘A litany of transnational crimes’

US District Court EDNY

The ‘scam empire’

AFP via Getty Images

French President Emmanuel Macron told European Union leaders to consider using the bloc’s most powerful trade tool against China if they aren’t able to find a resolution to Beijing’s planned export controls on critical raw materials.

Macron said they need to weigh using all options available against China, including the EU’s so-called anti-coercion instrument, according to people familiar with the matter.

(Bloomberg) — French President Emmanuel Macron told European Union leaders to consider using the bloc’s most powerful trade tool against China if they aren’t able to find a resolution to Beijing’s planned export controls on critical raw materials.

Most Read from Bloomberg

Macron said they need to weigh using all options available against China, including the EU’s so-called anti-coercion instrument, according to people familiar with the matter.

He made the statement to his counterparts during a leaders’ summit in Brussels Thursday, said the people, who spoke on the condition of anonymity. The French presidency didn’t respond to a request for comment.

“This is economic coercion,” Macron told reporters after the summit, referring to the Chinese announcement on rare earths, without commenting on the specifics of the closed-door conversation. “We can see the impact it is having on us and we need to be able to respond.”

China announced plans to significantly tighten controls on its exports of rare earths and other critical materials earlier this month. Under the measures, overseas exporters of items that use even traces of certain rare earths sourced from China would need an export license.

The export restrictions would pose a massive threat to Europe’s industry and security, as the inputs are critical across sectors and used in everything from electric vehicle batteries to defense manufacturing.

Following the summit, German Chancellor Friedrich Merz confirmed that the anti-coercion tool was discussed but that no decision had been reached on using it. He said it was now up to the European Commission, which handles trade matters for the EU, to decide whether to deploy the ACI.

The ACI, which has never been used, was designed primarily as a deterrent, and if needed, to respond to deliberate coercive actions from third countries that use trade measures as a means to pressure the policy choices of the EU or its members.

The instrument was created as part of the EU’s effort to boost its trade defenses after the US imposed tariffs on the bloc’s exports during the first Trump administration. Another factor was China’s decision to place restrictions on Lithuanian goods after Taiwan opened a trade office in the Baltic nation.

Use of the EU’s most potent trade tool is unlikely at this stage as it would significantly escalate tensions with China. France has called for using the instrument before, including during trade talks with the US. But the drive never fully gained traction.

The commission is currently working on options that it could use if a diplomatic solution with China isn’t found.

The commission is preparing a list of trade measures by the end of the month that can later be deployed against China to boost its negotiating leverage on the issue, Bloomberg reported earlier. The commission is also developing a plan to protect critical supplies in the short-term and secure other sources.

The EU’s trade chief Maros Sefcovic held talks with his Chinese counterpart, Wang Wentao, earlier this week on the proposed export restrictions.

“We have no interest in escalation,” Sefcovic told reporters after the call Tuesday. “However, this situation casts a shadow over our relationship, therefore a prompt resolution is essential.”

–With assistance from Alberto Nardelli and Arne Delfs.

(Updates with Macron quote in the fourth paragraph.)

Most Read from Bloomberg Businessweek

©2025 Bloomberg L.P.

(Reuters) -AI data centre startup Crusoe is raising $1.38 billion at a valuation of about $10 billion from an anticipated Series E funding round, the Denver-based company said on Thursday

The oversubscribed round is being co-led by Valor Equity Partners and Mubadala Capital and includes Nvidia, Fidelity Management and Founders Fund as some of its major investors.

The company, which was involved in building OpenAI’s first big data centre in the U.S., has raised about $3.9 billion since its inception in 2018.

It recently announced that the first phase of its 1.2 gigawatt data center in Abilene, Texas campus, was live just one year after construction began.

(Reporting by Anuj T in Bengaluru; Editing by Anil D’Silva)

The company, one of the largest U.S. makers of semiconductor manufacturing equipment, will take a charge of $160 million to $180 million for the layoffs, mostly in the fourth quarter of fiscal 2025, it disclosed in a regulatory filing.

Sign up here.

Late in September, Washington cracked down on companies in China and other countries that use subsidiaries or other foreign affiliates to circumvent export curbs on chipmaking equipment and other goods and technology.

That has made it harder for Applied Materials and its rivals to export some products and supply specific parts and services to select China-based customers without a license. The company earlier this month forecast a $600-million hit to its fiscal 2026 revenue due to the expanded curbs.

It said it started informing its employees about the layoffs earlier on Thursday. It had 35,700 full-time staff as of October 27, 2024, according to its annual report.

“Our goal is to continue to transform how we work, move faster, simplify decision-making, and focus on what matters most as we prepare Applied Materials for significant growth in the coming years,” CEO Gary Dickerson said in a memo to employees.

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Introduction

Background

Helicobacter pylori (H. pylori) infections correlate with chronic active gastritis, peptic ulcer development, gastric mucosa-associated lymphoid tissue lymphoma, gastric cancer, and other digestive diseases, as well as extradigestive disorders such as cardiovascular, hematologic, and autoimmune diseases [-]. A recent meta-analysis of data from 73 countries revealed a global H. pylori infection rate of 44.3%, higher in low- and middle-income countries (50.8%) than in high-income countries (34.7%), imposing significant economic burdens []. These findings underscore H. pylori’s pervasive harm, heightening global public health concerns for its eradication []. Standard triple and quadruple therapy combining proton pump inhibitors or bismuth with 2 antibiotics is established for H. pylori eradication [,]. However, despite widespread antibiotic use, eradication rates remain suboptimal, often due to antibiotic resistance and poor patient compliance [].

Poor patient compliance significantly impacts H. pylori eradication treatment as it increases the risk of treatment failure and contributes to the development of secondary antibiotic resistance due to inadequate drug dosages [,]. According to research involving a large patient cohort, those with good compliance, defined as completing over 80% of prescribed medication regimens, achieved eradication rates of 85% to 94%, whereas those with poor compliance achieved rates of only 39% to 53% []. Various factors influence patient compliance, including the complexity of the eradication regimen, treatment duration, adverse reactions, physician motivation, and patient awareness [,]. Currently, the prevailing eradication regimen typically lasts 7 to 14 days and involves administering 3 to 4 drugs before or after meals []. However, the regimen’s complexity and extended duration pose challenges for both physicians and patients, prompting widespread discussion among gastroenterologists on how to effectively address this issue.

Objectives

To combat poor patient compliance in H. pylori eradication treatment, various strategies have been implemented to enhance medication adherence, including health education, information communication, medication guidance, feedback on adverse drug reactions, and regular question-and-answer sessions. The emergence of new media technologies—such as telephone-supported follow-ups, SMS text messaging, and social media– or app-based modules—has opened up new avenues for patient education and supervision. In this review, we define new media–based education (NME) as a form of patient education and adherence support distinct from traditional oral or paper-based approaches. It is digitally delivered and interactive, implemented through mobile or networked platforms (eg, telephone-supported follow-ups, SMS text messaging, and various social media– or software-based applications). NME typically incorporates targeted communication and reminders, multimedia educational content, and bidirectional messaging in alignment with established digital health (mobile health) frameworks [-]. Despite its widespread use, the precise impact of NME on H. pylori eradication remains uncertain. Three meta-analyses published in 2022 suggested that enhanced educational interventions may improve eradication rates and patient compliance without increased adverse events [-]. However, these reviews were limited by relatively small sample sizes and the absence of comprehensive subgroup analyses, leaving uncertainties regarding the consistency and generalizability of their findings. To address these gaps, we conducted an updated and more comprehensive meta-analysis to evaluate the efficacy of NME in improving H. pylori treatment outcomes.

Methods

Registration and Implementing Guidance

This study adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and was registered on PROSPERO under registration number CRD42024517954.

Search Strategy

We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from inception to February 2025. The review protocol was registered in PROSPERO in February 2024, and an updated search was conducted in February 2025 to ensure the inclusion of the most recent studies. Eligible study designs included randomized controlled trials (RCTs) and retrospective cohort studies evaluating NME interventions for patients with H. pylori infection. The search strategy combined MeSH (Medical Subject Headings) terms and free-text keywords such as “Helicobacter pylori,” “patient education,” “educational technology,” “mobile phone applications,” “smartphone,” “short message service (SMS),” “text messaging,” “WeChat,” “tele-education,” “internet,” and “telemedicine” using Boolean operators (AND and OR) to maximize sensitivity. An example search string for PubMed was as follows: (“Helicobacter pylori” OR “H. pylori”) AND (“patient education” OR “health education” OR “educational technology” OR “mobile phone” OR “cell phone” OR “smartphone” OR “text message*” OR “short message service” OR “SMS” OR “WeChat” OR “tele-education” OR “telemedicine” OR “digital health”) AND (“randomized controlled trial” OR “controlled clinical trial” OR “cohort study”). The reference lists of the included studies and relevant reviews were also screened to identify additional eligible articles. The complete and detailed search strategies for each database are provided in in accordance with the PRISMA 2020 reporting guidelines.

Study Selection

Two investigators independently screened the initially retrieved bibliography using a 2-stage screening process. Any discrepancies were resolved through discussion or consultation with a third investigator. In the first phase, duplicates were automatically removed, followed by manual removal of any remaining duplicates. Studies were excluded based on inclusion and exclusion criteria by reviewing titles, abstracts, and full texts.

The following inclusion criteria were used in this study: (1) participants were individuals with H. pylori infection confirmed via rapid urease test, urea breath test, stool antigen test, culture, or histology with at least one positive result and who had not previously received eradication therapy; (2) the intervention was implementation of NME methods, such as telephone-based follow-up, SMS text messaging, or mobile apps, in combination with a standard eradication regimen (triple or quadruple therapy); (3) the comparator was a standard eradication regimen with conventional oral or written instructions; (4) the primary outcomes included H. pylori eradication rate and patient compliance, and the secondary outcomes included adverse events and patient satisfaction; and (5) the study design was RCTs and retrospective cohort studies. Retrospective studies were included due to limited available evidence and their comparable design and intervention quality to those of RCTs. The exclusion criteria were as follows: (1) publications in the form of comments, letters, protocols, conference abstracts, or reviews; (2) studies with insufficient data or duplicate reports; and (3) ongoing studies without available results.

Data Extraction

Two independent investigators extracted data from eligible studies using a predefined data collection form. Discrepancies were resolved through consensus. Extracted data included study characteristics, patient demographics, outcomes, and details of risk-of-bias assessment.

Risk-of-Bias Assessment

The methodological quality of the included studies was independently assessed by 2 reviewers, with disagreements resolved by a third reviewer. For RCTs, we applied the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), which evaluates 5 domains: bias arising from the randomization process, bias due to deviations from the intended intervention, bias due to missing outcome data, bias in measurement of the outcome, and bias in the selection of the reported results. Each domain was judged as “low risk,” “some concerns,” or “high risk,” and an overall risk-of-bias judgment was assigned accordingly. In total, 11 RCTs were evaluated using the RoB 2 tool.

For nonrandomized cohort studies, we used the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool, which assesses 7 domains: bias due to confounding, bias in the selection of participants, bias in classification of interventions, bias due to deviations from the intended intervention, bias due to missing data, bias in measurement of outcomes, and bias in the selection of the reported results. The overall risk of bias for cohort studies was categorized as low, moderate, serious, or critical. The 2 retrospective cohort studies included in this review were assessed using the ROBINS-I tool.

Statistical Analysis

We calculated risk ratios (RRs) and 95% CIs to evaluate associations between groups and outcomes. The primary outcomes were the pooled RRs of H. pylori eradication rate and patient compliance, whereas the secondary outcomes were pooled RRs of adverse events and patient satisfaction. We selected intention-to-treat (ITT) analysis as the primary approach because of its stronger scientific rationale, greater clinical applicability, and its ability to reflect real-world practice. Although some of the included studies (10/13, 77%) reported per-protocol (PP) data, only 69% (9/13) provided PP results for eradication, and just 31% (4/13) provided PP results for compliance. Given this limited number, it was not feasible to conduct meaningful subgroup analyses based on PP data, and conducting a pooled PP analysis under such circumstances would have resulted in too small a sample size, thereby reducing statistical robustness and potentially introducing bias. Consequently, we relied exclusively on ITT analysis to ensure the consistency, validity, and reliability of the findings while also minimizing the risk of selective reporting.

Heterogeneity was assessed using the I² statistic, with thresholds of 25%, 50%, and 75% representing low, moderate, and high heterogeneity, respectively. In line with current recommendations, we used a random-effects model for all meta-analyses to account for potential between-study heterogeneity and provide more conservative estimates.

Prespecified subgroup analyses were conducted to explore potential sources of heterogeneity. Subgroups were stratified according to intervention type (WeChat, telephone, telephone combined with other methods, and SMS text messaging), treatment regimen (triple vs quadruple therapy), age group (≤60 vs >60 years), country socioeconomic status (high income vs low and middle income), whether baseline outpatient education was provided, and whether WeChat group functionality was used.

Sensitivity analyses were conducted by sequentially excluding each study to assess its influence on the overall effect size.

Compliance definitions varied among studies, with 100% compliance defined as taking the prescribed dose. Publication bias was assessed using funnel plots, the Egger linear regression test, and the Begg rank correlation test. All primary meta-analyses were conducted using RevMan (version 5.4.1; The Cochrane Collaboration). Additional statistical analyses, including sensitivity analyses and publication bias assessments, were conducted using the Comprehensive Meta-Analysis software (version 3.0; Biostat, Inc).

Results

Study Flow

Our initial search identified 476 potentially relevant clinical trials. After thorough review and screening, of the 476 studies, 11 (2.3%) RCTs and 2 (0.4%) retrospective cohort studies [-] met the inclusion criteria and were included in the meta-analysis. The study selection process is detailed in .

Risk of Bias

Using the RoB 2 tool [], most of the 11 (85%) included RCTs were judged to be at low risk of bias, with some concerns mainly related to the randomization process and missing outcome data; no trial was rated as high risk (Figure S1A in ). The 2 retrospective cohort studies were assessed using the ROBINS-I tool [], which indicated a moderate risk of bias for one study [] and a serious risk for another [], largely due to confounding and limitations in participant selection and outcome measurement (Figure S1B in ).

Study Characteristics

The basic characteristics of the 13 eligible studies [-] are summarized in . These trials, conducted between 1999 and 2023, had sample sizes ranging from 80 to 566 participants, totaling 2942 across all studies. In total, 23% (3/13) of the trials [-] were conducted in high-income countries (England, the United States, and Australia), whereas the remaining 77% (10/13) [-] were conducted in low- and middle-income countries (China and Jordan). A total of 92% (12/13) of the studies [-,] reported on the eradication rate of H. pylori, 100% (13/13) [-] reported on patient compliance, 69% (9/13) [,,,,-,] reported on adverse events, and 23% (3/13) [,,] reported on patient satisfaction. The H. pylori eradication regimens included triple and quadruple therapies, with durations ranging from 7 to 14 days (). Control group patients received traditional oral and written medical instructions, whereas experimental group patients received additional intensive education instructions.

Primary Outcome

H. pylori Eradication Rate

A total of 92% (12/13) of the studies involving 2819 patients reported data on patient H. pylori eradication rates. ITT analysis showed that eradication rates were significantly higher in the NME group compared with the control group (81.9% vs 67%; RR 1.22, 95% CI 1.11-1.33; P<.001; A [-]). A high level of heterogeneity was detected among the included studies (I²=78%; P<.001), but sensitivity analysis confirmed the stability of the results (A).

‎

Subgroup Analysis of H. pylori Eradication Rate

Heterogeneous results require subgroup analysis. Subgroup analysis included different new media devices, different medication regimens, different age groups, the socioeconomic status of the country of origin, whether initial outpatient education was provided, and whether WeChat group functionality was used in conjunction with WeChat. In the intervention method subgroup, patients were categorized into WeChat, telephone, telephone with other methods, and SMS text messaging. In the medication regimen subgroup, patients were categorized into quadruple therapy and triple therapy. In the subgroup analysis of different populations, individuals were divided into age groups of ≤60 and >60 years and into high-income and low- and middle-income country groups based on the country of origin.

First, subgroup analyses were stratified according to different intervention methods. The intervention group had higher eradication rates in the WeChat subgroup (RR 1.27, 95% CI 1.10-1.47; P=.002; B). However, there was no difference in eradication rates between the intervention and control groups in the telephone (RR 1.11, 95% CI 1.00-1.23; P=.05), telephone with other methods (RR 1.26, 95% CI 0.98-1.61; P=.07), and SMS text messaging (RR 1.10, 95% CI 0.95-1.26; P=.21; B) subgroups. Subgroup analyses were then stratified according to different medication regimens. The intervention group had higher eradication rates than the control group in the quadruple therapy subgroup (RR 1.24, 95% CI 1.11-1.37; P<.001) but not in the triple therapy subgroup (RR 1.16, 95% CI 0.91-1.48; P=.23; C). In addition, compared to the control group, individuals aged ≤60 years had higher H. pylori eradication rates after NME (RR 1.21, 95% CI 1.02-1.44; P=.03), whereas those aged >60 years did not (RR 1.21, 95% CI 0.91-1.60; P=.18; A [-]). Interestingly, individuals from low- and middle-income countries showed significantly increased H. pylori eradication rates after NME compared to the control group (RR 1.24, 95% CI 1.13-1.37; P<.001), whereas there was no impact on individuals from high-income countries (RR 1.08, 95% CI 0.79-1.50; P=.62; B). Regardless of whether routine outpatient H. pylori eradication education was provided, NME yielded higher eradication rates in both the traditional (RR 1.22, 95% CI 1.03-1.43; P=.02) and nontraditional (RR 1.22, 95% CI 1.08-1.37; P=.002; C) education subgroup. Finally, using WeChat as a new media platform for H. pylori education, there was no significant difference in H. pylori eradication rates between the NME group and the control group when the WeChat group functionality was used (RR 1.21, 95% CI 0.93-1.58; P=.16; A [-]). However, when using WeChat for one-on-one education or other functionalities, the NME group showed higher H. pylori eradication rates (RR 1.31, 95% CI 1.08-1.59; P=.006; A). When the treatment duration was 14 days (RR 1.26, 95% CI 1.14-1.39; P<.001), the H. pylori eradication rate in the NME group was consistently higher than that in the control group (Figure S2A in ). However, when the duration was less than 14 days (RR 1.06, 95% CI 0.85-1.32; P=.61), there was no significant difference in eradication rates between the 2 groups (Figure S2A in ).

‎

‎

Patient Compliance

All 13 studies, involving 2942 patients, reported data on patient adherence. The analysis showed that patients in the NME group had significantly higher medication adherence compared to those in the control group (90.5% vs 73%; RR 1.27, 95% CI 1.15-1.40; P<.001; A [-]). There was high statistical heterogeneity between studies (I²=89%; P<.001), whereas sensitivity analysis showed stable results (A).

‎

Subgroup Analysis of Compliance

A stratified analysis based on different NME methods and different medication regimens showed that the NME group clearly had better compliance than the control group using WeChat (RR 1.23, 95% CI 1.06-1.43; P=.005), telephone (RR 1.13, 95% CI 1.05-1.22; P=.002), telephone with other methods (RR 1.57, 95% CI 1.06-2.34; P=.02), SMS text messaging (RR 1.16, 95% CI 1.03-1.30; P=.01; B), triple therapy regimen (RR 1.56, 95% CI 1.19-2.04; P=.001), or quadruple therapy regimen (RR 1.12, 95% CI 1.05-1.20; P<.001; C). A stratified analysis based on patient age showed that NME group clearly had better compliance than the control group in the group aged ≤60 years (RR 1.14, 95% CI 1.04-1.26; P=.006) but not in the group aged >60 years (RR 0.99, 95% CI 0.69-1.42; P=.95; A). Another stratified analysis based on whether the patients were from high-income countries showed that the NME group clearly had better compliance than the control group in both the low- and middle-income country subgroup (RR 1.21, 95% CI 1.10-1.33; P<.001) and the high-income country subgroup (RR 1.80, 95% CI 1.12-2.89; P=.01; B [-]). Similarly, based on whether basic outpatient education was provided to all enrolled patients, the NME group clearly had better compliance than the control group in both the traditional education subgroup (RR 1.27, 95% CI 1.02-1.57; P=.03) and the nontraditional education subgroup (RR 1.28, 95% CI 1.14-1.44; P<.001; C). A stratified analysis based on whether WeChat group re-education was used showed that new media significantly increased patient compliance in the non-WeChat subgroup (RR 1.31, 95% CI 1.08-1.59; P=.009) but not in the WeChat subgroup (RR 1.21, 95% CI 0.93-1.58; P=.28; B). In the subgroup with a 14-day treatment duration, patient compliance was significantly higher in the NME group than in the control group (RR 1.24, 95% CI 1.12-1.37; P<.001; Figure S2B in ). In contrast, in regimens lasting less than 14 days, compliance did not differ significantly between the 2 groups (RR 1.65, 95% CI 0.97-2.82; P=.07; Figure S2B in ).

‎

Secondary Outcomes

Adverse Events

Adverse drug reactions were documented in 69% (9/13) of the studies. The primary adverse events reported included diarrhea, constipation, nausea, abdominal pain, taste disorder, and skin rash. No significant differences were found between the NME and control groups (RR 0.88, 95% CI 0.71-1.09; P=.23; Figure S3A in ). Although significant heterogeneity was present among the studies (I²=63%; P<.001), the findings remained stable in sensitivity analysis (Figure S3A in ).

Patient Satisfaction

A total of 23% (3/13) of the studies, involving 672 patients, provided data on patient satisfaction. Patient satisfaction in the NME group was notably higher than that in the control group (61% vs 47.7%; RR 1.30, 95% CI 1.13-1.49; P<.001). Low statistical heterogeneity was observed (I²=0%; P=.47; Figure S3B in ).

Sensitivity and Publication Bias Analyses

The results of this study revealed some statistical heterogeneity, which may be attributed to factors such as intervention frequency, intervention duration, patient source (ie, patients from high-income vs low- and middle-income countries), and variation in eradication regimens. Given that heterogeneity is a major concern in meta-analysis, we conducted sensitivity analyses by sequentially excluding individual studies. The pooled results for all 4 main outcomes (H. pylori eradication rate, patient compliance, adverse events, and patient satisfaction) remained stable. In addition, subgroup analyses were conducted according to intervention type, treatment regimen, age group, country socioeconomic status, provision of baseline outpatient education, and use of the WeChat group functionality.

For publication bias, we first conducted visual inspection of funnel plots and then applied the Egger linear regression test and Begg rank correlation test for the 2 primary outcomes (H. pylori eradication rate and patient compliance) as both included ≥10 studies. Although mild asymmetry was observed in the funnel plots upon visual inspection (Figure S4 in ), statistical tests did not suggest significant publication bias. For H. pylori eradication rate, the Egger test resulted in P=.93, whereas the Begg test showed a Kendall tau with continuity correction of −0.05 (P=.84). Similarly, for patient compliance, the Egger test resulted in P=.20, and the Begg test reported a Kendall tau with continuity correction of 0.32 (P=.13). These findings indicate a low likelihood of publication bias; however, the slight visual asymmetry warrants cautious interpretation of the results.

Discussion

Principal Findings

This meta-analysis delved into the impact of NME on H. pylori eradication rates using platforms such as the internet or mobile communication. Overall, NME exhibited superiority over traditional education in both H. pylori eradication rates and patient compliance. Specifically, interventions via WeChat demonstrated clear advantages over telephone and SMS text messaging interventions. However, in comparison to traditional education, NME did not significantly ameliorate the overall occurrence rate or specific adverse reactions.

Compared with previous meta-analyses [-], our study included a larger and more recent set of trials (13 studies up to February 2025), thereby enhancing statistical power and ensuring that the evidence reflected the latest data. Moreover, we conducted more comprehensive subgroup analyses, not only covering intervention type, treatment regimen, patient satisfaction, and adverse events but also further exploring patient age, country socioeconomic status, provision of baseline outpatient education, and WeChat intervention models (personalized one-on-one vs group based). These additional analyses allowed us to better explain heterogeneity and provide novel insights into the applicability and optimization of NME strategies across different populations and social contexts.

Patient compliance stands as a pivotal factor contributing to the poor eradication rate of H. pylori. Adequate compliance is pivotal for ensuring the correct implementation of any eradication program, whereas poor compliance often leads to failure [,]. Therefore, educational interventions aimed at enhancing patient compliance are essential. Particularly with quadruple therapy, which yields better H. pylori eradication effects than triple therapy but entails a broader spectrum of drugs and necessitates more frequent dosing, patients may easily overlook or miss doses []. Thus, based on the findings of this study, NME significantly bolsters H. pylori eradication rates in the quadruple therapy population.

Compared to other strategies to enhance eradication rates, such as selecting antibiotics based on drug susceptibility, educational interventions are deemed cost-effective and straightforward []. Furthermore, education can augment patient awareness of H. pylori, foster self-management, and facilitate physician-patient communication []. NME holds even more promise than traditional education methods as it equips patients to better comprehend treatment regimens, provides convenient information on adverse drug reactions and health knowledge, and offers more interactive solutions to patients’ issues []. Particularly in low- and middle-income countries, where the average educational attainment level may not match that of high-income nations, repetitive education via new media can significantly enhance understanding and, thereby, improve H. pylori eradication rates.

The intervention measures used in the studies included in this review encompassed telephone follow-ups, SMS text message reminders, and WeChat consultations. WeChat interventions were used in 38% (5/13) of the studies, all of which showcased its effectiveness in enhancing the eradication rate. WeChat serves as a valuable platform for timely communication between patients and physicians, facilitating the prompt resolution of medication-related issues.

It is pertinent to note the limitations of emerging technologies such as WeChat. The inference drawn from this study is that older individuals, who are less inclined to adopt electronic devices, may not derive as much benefit from WeChat software education. Conversely, younger and middle-aged individuals exhibit greater receptiveness to new technologies, thereby perfectly exemplifying the advantages of WeChat education. Notably, our findings suggest that education delivered through WeChat groups may be less effective compared to one-on-one interactions. This difference may be attributed to several factors. First, group-based education often lacks personalization and may dilute individual responsibility, leading to lower engagement. Second, patients may be reluctant to discuss personal health issues in a group setting due to perceived privacy concerns. Third, the passive nature of group messages can result in reduced attentiveness and limited interaction. In contrast, stand-alone applications or supervised one-on-one education offer more tailored support, thereby enhancing compliance and H. pylori eradication rates. Due to the absence of direct comparative studies across different NME delivery modes, the most effective approach or combination of methods remains uncertain.

The internet and smartphones have revolutionized information access, and mobile health apps can effectively deliver patient education []. Given the exponential growth of medical apps, evaluating their capacity to provide comprehensive health education is imperative [].

Enhancing patient compliance is not associated with potential adverse events. Given that treatment regimens usually incorporate antibiotics, side effects are often attributed to antibiotic-related adverse events []. However, different treatment schemes yield varying side effects, underscoring the significance of precisely defining adverse events in this context []. While fortified NME can mitigate adverse emotions and mild discomfort stemming from side effects through enhanced physician-patient communication, its efficacy in reducing the occurrence rate of side effects remains limited.

Given the limitations of certain studies, the findings of this review warrant cautious interpretation. Primarily, most studies (10/13, 77%) were conducted in Asia, with only 23% (3/13) originating from Western countries. This underscores the necessity for trials encompassing diverse ethnic groups as the H. pylori infection rate varies across geographic regions []. Consequently, prudence should be exercised when extrapolating the conclusions to other regions. Second, the overall sample size was relatively modest. The absence of multicenter and large-sample studies amplifies the potential for bias and error, underscoring the need for additional rigorously designed experiments. Third, the interventions spanned a spectrum across the study sample, rendering it challenging to draw overarching conclusions. Meanwhile, although this review primarily relied on RCTs, it also included 2 retrospective cohort studies. Despite a certain level of comparability in terms of intervention content and study quality, it is important to note that differences in study design may introduce additional systematic bias, thereby weakening the strength of the conclusions. Finally, all fortified education methods engendered a selection bias toward specific demographic groups. For instance, WeChat education may not be viable for patients without smartphones. Consequently, these intervention measures may not fully capture patients with diverse educational backgrounds and economic statuses. Therefore, future research should prioritize the inclusion of more high-quality RCTs while also expanding intervention approaches tailored to diverse populations to enhance the external validity and generalizability of the findings.

Conclusions

In summary, the findings suggest that NME holds promise in increasing the H. pylori eradication rate, particularly when implemented via mobile phone apps. Nevertheless, intervention methods and designs exhibit considerable heterogeneity, necessitating ongoing high-quality research. Furthermore, the evolution of artificial intelligence technology has shifted the focus of medical and health education from the populace to the individual level. Hence, deliberating on the creation of personalized education programs and their integration into clinical practice is imperative.

This article first appeared on GuruFocus.

UnitedHealth Group (NYSE:UNH) reports third-quarter 2025 results before the market opens on October 28. Wall Street expects EPS of $2.79, down over 60% from last year on revenue of $113 billion, up approximately 12%. Shares have lost nearly 30% this year, despite a strong rally of nearly 30% after Warren Buffett (Trades, Portfolio)’s Berkshire Hathaway revealed a new stake in UnitedHealth.

Last quarter, UnitedHealth posted revenue of $112 billion, a 13% increase from the prior year, though profits fell sharply as medical-care costs surged and the company continued to deal with the impacts from February’s 2024 Optum cyber-attack. This quarter will test whether management has begun to get those expenses under control. Investors will focus on the medical care ratio (MCR), which rose above 89% last quarter, reflecting higher medical utilization and cost pressures. At the same time, attention will turn to Optum, where management acknowledged that its performance has not met expectations.

Guidance will also be key. After a difficult stretch, the market wants clarity on the pace of margin recovery heading into 2026. Management’s commentary around MCR, pricing discipline, and Optum’s growth trajectory will likely determine whether the stock can extend its rebound or lose momentum again.